ExCellThera rencontrera les investisseurs durant la 42e conférence annuelle J.P. Morgan Healthcare et participera aux prochaines conférences d'investisseurs
January 02, 2024 07:00 ET
|
ExCellThera
MONTREAL, 02 janv. 2024 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), un leader mondial des thérapies à base de cellules souches sanguines amplifiées, a annoncé aujourd'hui que ses hauts...
Cell BioEngines Enters Agreement with Miltenyi Bioindustry to Manufacture Hematopoietic Cell Therapy Clinical Program
December 29, 2023 18:13 ET
|
Cell BioEngines, Inc.
NEW YORK, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc., a clinical-stage biotechnology company focused on delivering novel, innovative stem cell and immune cell therapies to address blood...
ExCellThera annonce les résultats positifs des études de phase 2 de la thérapie cellulaire UM171 chez des patients atteints de leucémies et de myélodysplasies à haut risque lors du congrès annuel 2023 de l'American Society of Hematology (ASH)
December 12, 2023 07:00 ET
|
ExCellThera
- Données présentées lors d'une séance orale à l'ASH 2023, s'appuyant sur des données solides antérieures issues d'une étude de phase 1/2 et d'études comparatives de registres. - La thérapie...
ExCellThera Announces Positive Phase 2 Study Results from UM171 Cell Therapy in Patients with High-risk Leukemias and Myelodysplasias at American Society of Hematology (ASH) 2023 Annual Meeting
December 12, 2023 07:00 ET
|
ExCellThera
50 patients evaluated in Phase 2 studies; ExCellThera’s UM171 showed excellent clinical outcomes for this high-risk leukemia/myelodysplasia cohort
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
December 12, 2023 05:15 ET
|
ADC Therapeutics SA
Combination demonstrated clinically meaningful benefit in r/r FL patients with 96% overall response rate and 85% complete response rate LAUSANNE, Switzerland, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ADC...
Be The Match Announces Winners of 2023 NMDP/Be The Match Awards
November 27, 2023 10:21 ET
|
Be The Match
NMDP/Be The Match® announces the recipients of its annual NMDP/Be The Match Awards at The ONE Forum 2023.
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
November 09, 2023 16:01 ET
|
Vor Biopharma
Primary neutrophil engraftment of trem-cel achieved in all seven patients treated to dateAll three patients receiving multiple Mylotarg™ doses exhibited hematologic protection, further validating Vor...
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
November 07, 2023 16:05 ET
|
Vor Biopharma
Next trem-cel (VOR33) clinical data update expected by Relapse After Transplant and Cellular Therapy (HSCT2) Conference Nov 10-11Three oral abstracts and two poster presentations accepted at ASH 2023...
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline
November 07, 2023 07:30 ET
|
Adaptive Biotechnologies
Data generated by Adaptive’s next-generation sequencing-based MRD assay will support the development and commercialization of investigational medicines for hematologic malignancies SEATTLE, Nov. 07,...
ExCellThera announces new UM171 data to be presented at ASH 2023
November 03, 2023 08:15 ET
|
ExCellThera
ExCellThera announced today several UM171 presentations at ASH2023, including new data from Phase 2 studies in high-risk blood cancer patients